Carbapenem-Based Antibiotics Market Growth Outlook Through 2024-2033

Overview and Scope
Carbapenem-based antibiotics are a class of broad-spectrum antibiotics that are highly effective against many bacterial infections. Carbapenem antibiotics are commonly used to treat severe infections caused by gram-positive and gram-negative bacteria, including some strains resistant to other antibiotics.

Sizing and Forecast
The carbapenem-based antibiotics market size has grown strongly in recent years. It will grow from $4.43 billion in 2023 to $4.66 billion in 2024 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to epidemics and pandemics, rise in chronic diseases, healthcare infrastructure growth, rapid urbanization, natural disasters and health emergencies..

The carbapenem-based antibiotics market size is expected to see strong growth in the next few years. It will grow to $5.71 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to increased incidence of hospital-acquired infections, emergence of multi-drug resistant strains, growing aging population, rise in surgical procedures, proliferation of infectious diseases, changing demographics.. Major trends in the forecast period include supply chain resilience and security, alternative treatment development, shift towards outpatient settings, growing awareness on antimicrobial stewardship, precision medicine approaches..

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/carbapenem-based-antibiotics-global-market-report

Segmentation & Regional Insights
The carbapenem-based antibiotics market covered in this report is segmented –

1) By Type: Meropenem, Imipenem, Doripenem, Tebipenem, Other Types
2) By Indication: Intra-abdominal Infections, Urinary Tract Infections, Pneumonia, Bacterial Meningitis, Skin and Skin Structure Infections, Acute Pelvic Infections, Prophylaxis of Surgical Site Infection, Respiratory Tract Infections, Gynecological Infections, Other Indications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

North America was the largest region in the Carbapenem-Based Antibiotics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carbapenem-based antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12035&type=smp

Major Driver Impacting Market Growth
The increasing incidence of bacterial infections is expected to propel the growth of the carbapenem-based antibiotics market going forward. Bacterial infections are infections caused by bacteria, microscopic organisms that can invade the body and cause a range of diseases and symptoms. Carbapenem-based antibiotics treat severe or multidrug-resistant bacterial infections, including those caused by gram-positive and gram-negative bacteria. For Instance, In November 2022, according to the report published by the UK Health Security Agency (UKHSA), an executive government agency of the Department of Health and Social Care, in England, the anticipated total number of antibiotic-resistant severe infections increased by 2.2% in 2021. Therefore, an increased incidence of bacterial infections drives the growth of the carbapenem-based antibiotics market.

Key Industry Players
Major companies operating in the carbapenem-based antibiotics market report are Pfizer Inc., Merck & Co. Inc., Saint-Gobain S.A., Fresenius Kabi LLC, GlaxoSmithKline Plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Meiji Holdings Co. Ltd., Sandoz International GmbH, Sumitomo Dainippon Pharma Co. Ltd., Shionogi & Co Ltd., Aurobindo Pharma Ltd., Acurx Pharmaceuticals LLC, Daewoong Pharmaceutical Co. Ltd., CeramTec GmbH, ACS Dobfar S.p.A, JW Pharmaceutical Corp, Centrient Pharmaceuticals Co, Spero Therapeutics Inc., Kopran Limited, Savior Lifetec Corporation, Amedica Corporation, Flagship Biotech International Pvt. Ltd., Iterum Therapeutics plc, Cam Carbapenem-based antibiotics BV, Intelicure Lifesciences, Ikeda Corporation

The carbapenem-based antibiotics market report table of contents includes:

1. Executive Summary
2. Carbapenem-Based Antibiotics Market Characteristics
3. Carbapenem-Based Antibiotics Market Trends And Strategies
4. Carbapenem-Based Antibiotics Market – Macro Economic Scenario
5. Global Carbapenem-Based Antibiotics Market Size and Growth
.
.
.
32. Global Carbapenem-Based Antibiotics Market Competitive Benchmarking
33. Global Carbapenem-Based Antibiotics Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Carbapenem-Based Antibiotics Market
35. Carbapenem-Based Antibiotics Market Future Outlook and Potential Analysis
36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model